Moderna decreases mRNA production with Lonza in Switzerland, brings some manufacturing in-house
Moderna is now decreasing production of mRNA substance at a Lonza plant in Switzerland as the market for Covid-19 vaccines wanes and the company’s ambitious plans to launch new products and mRNA medicines outside of Covid move forward.
In a Tuesday statement, Moderna said doing so will “right-size” its manufacturing strategy to be more in line with current vaccine demands. It plans to largely handle manufacturing on its own.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.